Xizang Weixinkang Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 219 million yuan, a year-on-year decrease of 9.9%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Xizang Weixinkang Pharmaceutical disclosed its third-quarter report for 2025. The company achieved revenue of 862 million yuan in the first three quarters, a year-on-year decrease of 13.27%; net profit attributable to the parent company was 219 million yuan, a year-on-year decrease of 9.9%; net profit excluding non-recurring gains and losses was 169 million yuan, a year-on-year decrease of 14.01%; basic earnings per share were 0.51 yuan
According to the Zhitong Finance APP, Xizang Weixinkang Pharmaceutical (603676.SH) disclosed its third-quarter report for 2025. The company achieved revenue of 862 million yuan in the first three quarters, a year-on-year decrease of 13.27%; net profit attributable to shareholders was 219 million yuan, a year-on-year decrease of 9.9%; net profit excluding non-recurring gains and losses was 169 million yuan, a year-on-year decrease of 14.01%; basic earnings per share were 0.51 yuan